Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 758-787

  Reiner, Anton ^a   Heldt, Scott A ^a   Presley, Chaela S ^a   Guley, Natalie H ^a   Elberger, Andrea J ^a   Deng, Yunping ^a   D'Surney, Lauren ^a   Rogers, Joshua T ^a   Ferrell, Jessica ^a   Bu, Wei ^a   Del Mar, Nobel ^a   Honig, Marcia G ^a   Gurley, Steven N ^a   Moore, Bob M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

CB2 receptors; Deficits; Microglia; TBI; Therapy

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CHEMOKINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SMM 189; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; BENZOPHENONE DERIVATIVE; CALCIUM BINDING PROTEIN; CYTOKINE; SMM-189;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONDITIONED RESPONSE ANXIETY TEST; CONTROLLED STUDY; DEPRESSION; DIFFUSE AXONAL INJURY; EMOTIONAL DISORDER; FEAR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MORPHOMETRICS; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; TAIL SUSPENSION TEST; TRAUMATIC BRAIN INJURY; VISUAL ACUITY; VISUAL DISORDER; AGONISTS; ANIMAL; BRAIN INJURIES; C57BL MOUSE; CELL CULTURE; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; INVERSE AGONISM; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PHENOTYPE; VISION DISORDERS;

MUS;

ANIMALS; BENZOPHENONES; BRAIN INJURIES; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; CHEMOKINES; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG INVERSE AGONISM; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; MOTOR ACTIVITY; PHENOTYPE; RECEPTOR, CANNABINOID, CB2; VISION DISORDERS;

EID: 84920263096     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010758     Document Type: Article

References (86)

1. Risdall, J.E.; Menon, D.K. Traumatic brain injury. Phil. Trans. R. Soc. 2011, 366, 241–250.
2. Faul, M.; Xu, L.; Wald, M.M.; Coronado, V.G. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths, 2002–2006; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010.
3. Johnson, V.E.; Stewart, W.; Smith, D.H. Axonal pathology in traumatic brain injury. Exper. Neurol. 2013, 246, 35–43.
4. Bazarian, J.J.; Donnelly, K.; Peterson, D.R.; Warner, G.C.; Zhu, T.; Zhong, J. The relation between posttraumatic stress disorder and mild traumatic brain injury acquired during operations enduring freedom and Iraqi freedom. J. Head Trauma Rehabil. 2013, 28, 1–12.
5. Namjoshi, D.R.; Good, C.; Cheng, W.H.; Panenka, W.; Richards, D.; Cripton, P.A.; Wellington, C.L. Towards clinical management of traumatic brain injury: A review of models and mechanisms from a biomechanical perspective. Dis. Models Mech. 2013, 6, 1325–1338.
6. Xiong, Y.; Mahmood, A.; Chopp, M. Animal models of traumatic brain injury. Nat. Rev. Neurosci. 2013, 14, 128–142.
7. Kelley, B.J.; Lifshitz, J.; Povlishock, J.T. Neuroinflammatory responses after experimental diffuse traumatic brain injury. J. Neuropathol. Exp. Neurol. 2007, 66, 989–1001.
8. Redell, J.B.; Dash, P.K. Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia. Neurosci. Lett. 2007, 413, 36–41.
9. Cao, T.; Thomas, T.C.; Ziebell, J.M.; Pauly, J.R.; Lifshitz, J. Morphological and genetic activation of microglia after diffuse traumatic brain injury in the rat. Neuroscience2012, 225, 65–75.
10. Das, M.; Mohapatra, S.; Mohapatra, S.S. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J. Neuroinflamm. 2012, 9, 236–247.
11. Kumar, A.; Loane, D.J. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain Behav. Immun. 2012, 26, 1191–1201.
12. Patterson, Z.R.; Holahan, M.R. Understanding the neuroinflammatory response following concussion to develop treatment strategies. Front. Cell. Neurosci. 2012, 6, 58–90.
13. Perez-Polo, J.R.; Rea, H.C.; Johnson, K.M.; Parsley, M.A.; Unabia, G.C.; Xu, G.; Infante, S.K.; Dewitt, D.S.; Hulsebosch, C.E. Inflammatory consequences in a rodent model of mild traumatic brain injury. J. Neurotrauma2013, 30, 727–740.
14. Smith, C.; Gentleman, S.M.; Leclercq, P.D.; Murray L.S.; Griffin W.S.; Graham D.I.; Nicoll J.A. The neuroinflammatory response in humans after traumatic brain injury. Neuropathol. Appl. Neurobiol. 2013, 39, 654–666.
15. Heldt, S.A.; Elberger, A.J.; Deng, Y.; Guley, N.H.; del Mar, N.; Rogers, J.; Choi, G.W.; Ferrell, J.; Rex, T.S.; Honig, M.G.; et al. A novel closed-head model of mild traumatic brain injury caused by primary overpressure blast to the cranium produces sustained emotional deficits in mice. Front. Neurol. 2014, 5, 2–35.
16. Rex, T.; Elberger, A.J.; Deng, Y.; Guley, N.H.; D’Surney, L.; Hines-Beard, J.; del Mar, N.; Honig, M.G.; Reiner, A. Visual deficits in mice after mild traumatic brain injury produced using a novel closed-head model of primary overpressure blast. Investig. Ophthalmol. Vis. Sci. 2013, 54, 5095–B0053.
17. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014, 11, 98, doi:10.1186/1742-2094-11-98.
18. Schomberg, D.; Olson, J. Immune responses of microglia in the spinal cord: Contribution to pain states. Exp. Neurol. 2012, 234, 262–270.
19. Benito, C.; Núñez, E.; Tolón, RM.; Carrier, EJ.; Rábano, A.; Hillard, CJ.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J. Neurosci. 2003, 23, 11136–11141.
20. Stella, N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas. Glia 2010, 58, 1017–1030.
21. Baek, J.H.; Darlington, C.L.; Smith, P.F.; Ashton, J.C. Antibody testing for brain immunohistochemistry: Brain immunolabeling for the cannabinoid CB2 receptor. J. Neurosci. Methods2013, 216, 87–95.
22. Ashton, J.C.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol.2007, 5, 73–80.
23. Romero-Sandoval, E.A.; Horvath, R.; Landry, R.P.; DeLeo, J.A. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol. Pain2009, 5, 25.
24. Arévalo-Martín, A.; Vela J.M.; Molina-Holgado E.; Borrell J.; Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003, 23, 2511–2516.
25. Palazuelos, J.; Aguado, T.; Pazos, M.R.; Julien, B.; Carrasco, C.; Resel, E.; Sagredo, O.; Benito, C.; Romero, J.; Azcoitia, I.; et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 2009, 132, 3152–3164.
26. Rivers, J.R.J.; Ashton, J.C. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10, 47–64.
27. Schmidt, W.; Schäfer, F.; Striggow, V.; Fröhlich, K.; Striggow, F. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. Neuroscience2012, 227, 313–326.
28. Mechoulam, R.; Spatz, M.; Shohami, E. Endocannabinoids and neuroprotection. Science 2002, 2002, re5, doi:10.1126/stke.2002.129.re5.
29. Meyer, M.J.; Megyesi, J.; Meythaler, J.; Murie-Fernandez, M.; Aubut, J.A.; Foley, N.; Salter, K.; Bayley, M.; Marshall, S.; Teasell, R. Acute management of acquired brain injury part II: An evidence-based review of pharmacological interventions. Brain Inj. 2010, 24, 706–721.
30. Elliott, M.B.; Tuma, R.F.; Amenta, P.S.; Barbe, M.F.; Jallo, J.I. Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J. Neurotrauma2011, 28, 973–981.
31. Amenta, P.S.; Jallo, J.I.; Tuma, R.F.; Elliott, M.B. A cannabinoid type-2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J. Neurosci. Res. 2012, 90, 2293–2305.
32. Firsching, R.; Piek, J.; Skalej, M.; Rohde, V.; Schmidt, U.; Striggow, F.; KN38–7271 Study Group. Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38–7271: A randomized, double-blind, placebo-controlled phase II trial. J. Neurol. Surg. 2012, 73, 204–216.
33. Koppel, J.; Vingtdeux, V.; Marambaud, P.; D’Abramo, C.; Jimenez, H.; Stauber, M.; Friedman, R.; Davies, P. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease. Mol. Med.2013, 20, 29–36.
34. Lopez-Rodriguez, A.B.; Siopi, E.; Finn, D.P.; Marchand-Leroux, C.; Garcia-Segura, L.M.; Jafarian-Tehrani, M.; Viveros, M.P. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb. Cortex2013, doi:10.1093/cercor/bht202.
35. Lunn, C.; Fine, J.; Rojas-Triana, A.; Jackson, J.; Fan, X.D.; Kung, T.; Gonsiorek, W.; Schwarz, M.; Lavey, B.; Kozlowski, J.; et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 2006, 316, 780–788.
36. Lunn, C.; Reich, E.P.; Fine, J.; Lavey, B.; Kozlowski, J.; Hipkin, R.; Lundell, D.; Bober, L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br. J. Pharmacol. 2008, 153, 226–239.
37. Atwood, B.K.; Straiker, A.; Mackie, K. CB2: Therapeutic target-in-waiting. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 2012, 38, 16–20.
38. Lawrence, T.; Natoli, G. Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat. Rev. Immunol. 2011, 11, 750–761.
39. Bhattacharjee, H.; Gurley, S.N.; Moore, B.M. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. Bioorg. Med. Chem. Lett. 2009, 19, 1691–1693.
40. Fujinaga, M.; Kumata, K.; Yanamoto, K.; Kawamura, K.; Yamasaki, T.; Yui, J.; Hatori, A.; Ogawa, M.; Yoshida, Y.; Nengaki, N.; et al. Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg. Med. Chem. Lett. 2010, 20, 1565–1568.
41. Tang-Schomer, M.D.; Patel, A.R.; Baas, P.W.; Smith, D.H. Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. FASEB J. 2010, 24, 1401–1410.
42. Tang-Schomer, M.D.; Johnson, V.E.; Baas, P.W.; Stewart, W.; Smith, D.H. Partial interruption of axonal transport due to microtubule breakage accounts for the formation of periodic varicosities after traumatic axonal injury. Exp. Neurol. 2012, 233, 364–372.
43. Love, S.; Louis, D.N.; Ellison, D.W. Trauma. In Greenfield’s Neuropathology, 8th ed.; Edward Arnold Publishers Ltd.: London, UK, 2008; pp. 733–812.
44. Smith, J.; Das, A.; Ray, S.; Banik, N. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 2012, 87, 10–20.
45. Petras, J.; Bauman, R.; Elsayed, N. Visual system degeneration induced by blast overpressure. Toxicology1997, 121, 41–49.
46. Koliatsos, V.E.; Cernak, I.; Xu, L.; Song, Y.; Savonenko, A.; Crain, B.J.; Eberhart, C.G.; Frangakis, C.E.; Melnikova, T.; Kim, H.; et al. A mouse model of blast injury to brain: Initial pathological, neuropathological, and behavioral characterization. J. Neuropathol. Exp. Neurol. 2011, 70, 399–416.
47. Wang, J.; Hamm, R.J.; Povlishock, J.T. Traumatic axonal injury in the optic nerve: Evidence for axonal swelling, disconnection, dieback, and reorganization. J. Neurotrauma2011, 28, 1185–1198.
48. Mohan, K.; Kecova, H.; Hernandez-Merino. E.; Kardon, R.H.; Harper, M.M. Retinal ganglion cell damage in an experimental rodent model of blast-mediated traumatic brain injury. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3440–3450.
49. Tzekov, R.; Quezada, A.; Gautier, M.; Biggins, D.; Frances, C.; Mouzon, B.; Jamison, J.; Mullan, M.; Crawford, F. Repetitive mild traumatic brain injury causes optic nerve and retinal damage in a mouse model. J. Neuropathol. Exp. Neurol. 2014, 73, 345–361.
50. Cockerham, G.C.; Goodrich, G.L.; Weichel, E.D.; Orcutt, J.C.; Rizzo, J.F.; Bower, K.S. Schuchard, R.A. Eye and visual function in traumatic brain injury. J. Rehabil. Res. Dev. 2009, 46, 811–818.
51. Warner, N.; Eggenberger, E. Traumatic optic neuropathy: A review of the current literature. Curr. Opin. Ophthalmol. 2010, 21, 459–462.
52. Peskind, P.R.; Brody, D.; Cernak, I.; McKee. A.; Ruff, R.L. Military- and sports-related mild traumatic brain injury: Clinical presentation, management, and long-term consequences. J. Clin. Psychiatry2013, 74, 180–188.
53. Di Leo, M.A.; Caputo, S.; Falsini, B.; Porciatti, V.; Minnella, A.; Greco, A.V.; Ghirlanda, G. Nonselective loss of contrast sensitivity in visual system testing in early type I diabetes. Diabetes Care1992, 15, 620–625.
54. Abe, H.; Hasegawa, S.; Takagi, M.; Yoshizawa, T.; Usui, T. Contrast sensitivity for the stationary and drifting vertical stripe patterns in patients with optic nerve disorders. Ophthalmalogica1993, 207, 100–105.
55. Hashemi, H.; Khabazkhoob, M.; Jafarzadehpur, E.; Emamian, M.H.; Shariati, M.; Fotouhi, A. Contrast sensitivity evaluation in a population-based study in Shahroud, Iran. Ophthalmology2012, 119, 541–546.
56. Marmor, M.F. Contrast sensitivity versus visual acuity in retinal disease. Br. J. Ophthalmol. 1986, 70, 553–559.
57. Al-Hashmi, A.M.; Kramer, D.J.; Mullen, K.T. Human vision with a lesion of the parvocellular pathway: An optic neuritis model for selective contrast sensitivity deficits with severe loss of midget ganglion cell function. Exp. Brain Res. 2011, 215, 293–305.
58. Akimov, N.P.; Renteria, R.C. Spatial frequency threshold and contrast sensitivity of an optomotor behavior are impaired in the Ins2Akita mouse model of diabetes. Behav. Brain Res. 2012, 226, 601–605.
59. Dräger, U.C.; Olsen, J.F. Origins of crossed and uncrossed retinal projections in pigmented and albino mice. J. Comp. Neurol. 1980, 191, 383–412.
60. Jovanović, M.; Bobić-Radovanović, A.; Vuković, D.; Knezević, M.; Risović, D. Ocular injuries caused by airsoft guns: Ten-year experience. Acta Chir Iugosl. 2012, 59, 73–76.
61. Hines-Beard, J.; Marchetta, J.; Gordon, S.; Chaum, E.; Geisert, E.E.; Rex, T.S. A novel mouse model of ocular blast injury. Exp. Eye Res. 2012, 99, 63–70.
62. Jasnow, A.M.; Ehrlich, D.E.; Choi, D.C.; Dabrowska, J.; Bowers, M.E.; McCullough, K.M.; Rainnie, D.G.; Ressler, K.J. Thy1-expressing neurons in the basolateral amygdala may mediate fear inhibition. J. Neurosci. 2013, 33, 10396–10404.
63. Herry, C.; Ciocchi, S.; Senn, V.; Demmou, L.; Müller, C.; Lüthi, A. Switching on and off fear by distinct neuronal circuits. Nature2008, 454, 600–606.
64. Gorski, J.A.; Talley, T.; Qiu, M.; Puelles, L.; Rubenstein, J.L.R.; Jones, K.R. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the emx1-expressing lineage. J. Neurosci. 2002, 22, 6309–6314.
65. Bareyre, F.M.; Kerschensteiner, M.; Misgeld, T.; Sanes, J.R. Transgenic labeling of the corticospinal tract for monitoring axonal responses to spinal cord injury. Nat. Med. 2005, 11, 1355–1360.
66. Drai, D.; Golani, I. SEE: A tool for the visualization and analysis of rodent exploratory behavior. Neurosci. Biobehav. Rev. 2001, 25, 409–426.
67. Drai, D.; Benjamini, Y.; Golani, I. Statistical discrimination of natural modes of motion in rat exploratory behavior. J. Neurosci. Methods2000, 96, 119–131.
68. Kafkafi, N.; Lipkind, D.; Benjamini, Y.; Mayo, C.L.; Elmer, G.I.; Golani, I. See locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions. Behav. Neurosci. 2003, 117, 464–477.
69. Kafkafi, N.; Mayo, C.; Drai, D.; Golani, I.; Elmer G. Natural segmentation of the locomotor behavior of drug-induced rats in a photobeam cage. J. Neurosci. Methods2001, 109, 111–121.
70. Lipkind, D.; Sakov, A.; Kafkafi, N.; Elmer, G.I.; Benjamini, Y.; Golani, I. New replicable anxiety-related measures of wall versus center behavior of mice in the open field. J. Appl. Physiol. 2004, 97, 347–359.
71. Reiner, A.; Lafferty, D.C.; Wang, H.B.; del Mar, N.; Deng, Y.P. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington’s disease mice. Neurobiol. Dis. 2012, 47, 75–91.
72. Prusky, G.T.; Alam, N.M.; Beekman, S.; Douglas, R.M. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Investig. Ophthalmol. Vis. Sci. 2004, 45, 4611–4616.
73. Rao, V.; Bertrand, M.; Rosenberg, P.; Makley, M.; Schretlen, D.J.; Brandt, J.; Mielke, M.M. Predictors of new-onset depression after mild traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 2010, 22, 100–104.
74. Cryan, J.F.; Mombereaqu, C.; Vassout, A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Res. 2005, 29, 571–625.
75. Mahan, A.L.; Ressler, K.J. Fear conditioning, synaptic plasticity and the amygdala: Implications for posttraumatic stress disorder. Trends Neurosci. 2012, 35, 24–35.
76. Cuthbertson, S.; LeDoux, M.S.; Jones, S.; Jones, J.; Zhou, Q.; Gong, S.; Ryan, P.; Reiner, A. Localization of preganglionic neurons that innervate choroidal neurons of pterygopalatine ganglion. Investig. Ophthalmol. Vis. Sci. 2003, 44, 3713–3724.
77. Meade, C.A.; Figueredo-Cardenas, G.; Fusco, F.R.; Nowak, T.S.; Pulsinelli, W.; Reiner, A. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington’s disease. Exper. Neurol. 2000, 166, 307–323.
78. Shitaka, Y.; Tran, H.T.; Bennett, R.E.; Sanchez, L.; Levy, M.A.; Dikranian, K.; Brody, D.L. Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J. Neuropathol. Exp. Neurol. 2011, 70, 551–567.
79. Kreutzberg, G.W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 1996, 19, 312–318.
80. Ebneter, A.; Casson, R.J.; Wood, J.P.; Chidlow, G. Microglial activation in the visual pathway in experimental glaucoma: Spatiotemporal characterization and correlation with axonal injury. Investig. Ophthalmol. Vis. Sci. 2010, 51, 6448–6460.
81. Acosta, S.A.; Tajiri, N.; Shinozuka, K.; Ishikawa, H.; Grimmig, B.; Diamond, D.M.; Sanberg, P.R.; Bickford, P.C.; Kaneko, Y.; Borlongan, C.V. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PLoS One2013, 8, e53376.
82. Bradbury, E.J.; Moon, L.D.; Popat, R.J.; King, V.R.; Bennett G.S.; Patel P.N.; Fawcett J.W.; McMahon, S.B. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature2002, 416, 636–640.
83. Saito, N.; Shirai, Y. Protein kinase Cγ (PKCγ): Function of neuron specific isotype. J. Biochem. 2002, 132, 683–687.
84. Lieu, A.; Tenorio, G.; Kerr, B.J. Protein kinase C gamma (PKCγ) as a novel marker to assess the functional status of the corticospinal tract in experimental autoimmune encephalomyelitis (EAE). J. Neuroimmunol. 2013, 256, 43–48.
85. Deng, Y.P.; Wong, T.; Bricker-Anthony, C.; Deng, B.; Reiner, A. Loss of corticostriatal and thalamostriatal synaptic terminals in heterozygous Q140 Huntington’s disease mice. Neurobiol. Dis. 2013, 60, 89–107.
86. Reiner, A.; del Mar, N.; Deng, Y.P.; Meade, C.A.; Sun, Z.; Goldowitz, D. R6/2 Neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 2007, 505, 603–629.